PCM
SUPN icon

Portolan Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Portolan Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,990
Closed -$470K – 137
2016
Q3 		$470K Sell
18,990
-195,794
-91% -$4.43M 0.06% 109
2016
Q2 		$4.38M Sell
214,784
-46,137
-18% -$818K 0.63% 62
2016
Q1 		$3.98M Buy
260,921
+78,132
+43% +$1.02M 0.53% 68
2015
Q4 		$2.46M Buy
+182,789
New +$2.83M 0.31% 96

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Portolan Capital Management's SUPN Position: Q4 2016 in Review

Portolan Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 18,990 shares — an estimated $470K sold.

Portolan Capital Management first reported a position in SUPN in Q4 2015 and held it in 4 quarters. The position peaked at $4.38M in Q2 2016. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • Portolan Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Portolan Capital Management sold 18,990 Supernus Pharmaceuticals shares in Q4 2016, an estimated $470K.
  • Portolan Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Portolan Capital Management's Supernus Pharmaceuticals position peaked at $4.38M in Q2 2016.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on Portolan Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.